Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Safety and tolerance of enteric-coated mycophenolate sodium in patients after kidney transplantation – an observational study

J Gozdowska, T Bączkowska, J Pazik, B Matłosz, T Cieciura, J Szmidt, A Chmura, M Durlik

Ann Transplant 2009; 14(1): 75-75 :: ID: 880477


Background: Enteric-coated mycophenolate sodium (MPS) has been developed as an alternative agent to mycophenolate mofetil (MMF), with aim to provide reduction in gastrointestinal (GI) complications.
Material/Methods: Between February 2006 and December 2007, 74 patients,
mean age 42.26 years, in whom MMF was switched to MPS were included in
the study. The mean time from transplantation to change in treatment was 3.69 years. Follow-up was 3 months (Visit 0, Visit 2 after 1 month and Visit 3 after 3 months). During Visit 2 and 3, the impact changing the treatment on the severity of GI symptoms was assessed on a scale from 1 to 4 (1 - wors-ening, 2 - no change, 3 - improvement, 4 - resolved). Tolerance of therapy, patient compliance and physician's satisfaction with treatment were also assessed (1 to 4 scale: 1 - bad, 2 - fair, 3 - good, 4 - very good). During Visits 2 and 3, adverse events (AEs) were recorded.
Results: Follow-up was completed in 63 patients (85.1%). Patients received MPS in doses ranging from 720 to 1440 mg (mean dose 1092 mg). The mean GI symptom severity score in the MMF to MPS conversion group was 3.41. The most common symptoms that were the reason for conversion were: abdominal pain, diarrhoea, abdominal colic, nausea, anorexia and vomiting. Out of 175 reported complaints 144 (82%) either improved or were completely resolved. Worsening was noted with regard to only 5 (2.86%) of reported complaints, and no change was seen in 25 (14.86%) symptoms. Patient's compliance was graded as 3.70 for Visit 3. Mean physician's satisfaction score assessed during the last visit was 3.02. 9 AEs (including 2 severe) were reported. Causal relationship with the medication was suspected in 5 cases (including 1 case of SAE). The most important AEs were: anaemia, infection (including 1 case of sepsis), GI symptoms (abdominal pain, diarrhoea).
Conclusions: 1. Sodium mycophenolate is well tolerated. 2. After switching from MMF to MPS, gastrointestinal symptoms decrease. 3. MPS is a safe
medication, with a low adverse event rate.

Keywords: Immunosuppression, Kidney Transplantation, clinical outcome

Add Comment 0 Comments

In Press

12 Feb 2024 : Original article  

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...

Ann Transplant In Press; DOI: 10.12659/AOT.942767  

21 Feb 2024 : Original article  

Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians

Ann Transplant In Press; DOI: 10.12659/AOT.943498  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358